Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Neuro-Oncology

Volumn 18, Issue 4, 2016, Pages 557-564

  Butowski, Nicholas ^a   Colman, Howard ^b   De Groot, John F ^c   Omuro, Antonio M ^d   Nayak, Lakshmi ^e   Wen, Patrick Y ^e   Cloughesy, Timothy F ^f   Marimuthu, Adhirai ^g   Haidar, Sam ^e   Perry, Arie ^a   Huse, Jason ^d   Phillips, Joanna ^a   West, Brian L ^g   Nolop, Keith B ^g   Hsu, Henry H ^g   Ligon, Keith L ^e   Molinaro, Annette M ^a   Prados, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g PLEXXIKON INC   (United States)

Author keywords

CSF1R; glioblastoma; glioma; microglia; PLX3397

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CD14 ANTIGEN; CD16 ANTIGEN; COLONY STIMULATING FACTOR 1; PLX 3397; UNCLASSIFIED DRUG; 5-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL)-N-((6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE; AMINOPYRIDINE DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; PYRROLE DERIVATIVE; TUMOR MARKER;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HAIR DISCOLORATION; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; TISSUE DISTRIBUTION; TUMOR RECURRENCE; TUMOR VOLUME;

ADMINISTRATION, ORAL; AMINOPYRIDINES; BIOMARKERS, TUMOR; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PYRROLES; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84966552295     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov245     Document Type: Article

References (20)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields. Semin Oncol. 2013;40(6):S2-S4.
3. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-1018.
4. Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15-24.
5. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
6. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
7. Rodero M, Marie Y, Coudert M, et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol. 2008;26(36):5957-5964.
8. Sielska M, Przanowski P, Wylot B, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol. 2013;230(3):310-321.
9. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272.
10. Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 2012;18:519-527.
11. Elmore MR, Najafi AR, Koike MA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380-397.
12. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
13. Phillips JJ, Aranda D, Ellison DW, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013;23(5):565-573.
14. Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res. 2014;20(19):5023-5031.
15. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
16. Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011;13(10):1118-1124.
17. Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20(12):3146-3158.
18. Engler JR, Robinson AE, Smirnov I, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PloS one. 2012;7(8):e43339.
19. Li B, Senbabaoglu Y, Peng W, et al. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. Clin Cancer Res. 2012;18(20):5595-5605.
20. Bhat KP, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331-346.